Jazz Pharmaceuticals Price Target Raised by RBC Capital to $151, Maintains Outperform Rating

RBC Capital analyst Gregory Renza has raised Jazz Pharmaceuticals' (JAZZ) price target to $151, up from $145, while maintaining an Outperform rating. The adjustment follows Jazz's recent investor call regarding Modeyso, a newly approved treatment for rare H3 K27M mutant gliomas. Renza expresses increased optimism about Modeyso's market potential due to higher than anticipated pricing and Jazz Pharmaceuticals' robust launch strategy.